Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06688422 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy

Study acronym: INSPIRE-CRT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Dec 2025 to Dec 2026 · Study sites: 0 to 1 · Completion date: Mar 2026 to Dec 2026 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Dec 2025 to Dec 2026
    • Study sites: 0 to 1
    • Completion date: Mar 2026 to Dec 2026
    • Start date changed from estimate of Nov 2024 to Dec 1, 2024
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are: Does using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life? Participants will: Use an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake. Continue using the spirometer daily during treatment and for up to three months after treatment. Complete quality of life assessments at the start of the study and at 3, 6, and 12 months. Researchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\' well-being during and after their cancer treatment.
Trial Details
NCT Number NCT06688422
Lead Sponsor The Cooper Health System
Collaborators: The Cooper Foundation
Conditions Lung Cancer, Pneumonitis, Radiation-Induced Lung Injury, Immunotherapy-Induced Pneumonitis, Non-Small-Cell Lung Cancer (NSCLC)
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov